Will the FDA approve INO-3107 for recurring airway tumours in its October 30 review cycle?

Question

This market resolves YES if the FDA approves INOVIO’s INO-3107 for adults with recurrent respiratory papillomatosis in the first review of the biologics application carrying an October 30, 2026 target action date. The question is about this DNA-based therapy for the named recurring airway disease, not a preventative HPV vaccine or treatment of every form of cancer.

INOVIO’s August update says the application remains under review. A target action date is an agency review goal, not a promise of a

Problyx · Accepted Answer

Yes — the community forecast puts this at 51%.

Problyx · Answer

No — the community forecast puts this at 49%.